Dr. Neil Iyengar & Dr. Mark Robson – PARP Inhibitors in Early Breast Cancer: Who and When to Treat

From testing to treatment, the conversation around PARP inhibition in breast cancer is rapidly evolving.

In this episode, Dr. Neil Iyengar and Dr. Mark Robson explore how germline testing, risk stratification, and therapy sequencing are shaping adjuvant treatment decisions for BRCA1/2-mutated breast cancer.

They discuss:
🔹 Who should be tested — and how testing criteria are expanding.
🔹 Key takeaways from OlympiA and long-term data on olaparib.
🔹 The balance between PARP inhibitors, CDK4/6 inhibitors, and IO-based regimens.
🔹 How toxicity, sequencing, and emerging biomarkers like MRD may guide the future of adjuvant therapy.

Stay ahead of the data in this forward-looking conversation on personalizing care for high-risk HER2-negative breast cancer.